X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/china-approves-astrazenecas-tagrisso-chemo-combo-first-line-treatment-2024-06-26/
https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer.html
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-aims-deliver-80-billion-total-revenue-by-2030-2024-05-21/
https://endpts.com/jury-says-astrazeneca-should-pay-pfizer-107m-over-tagrisso-infringement/
https://www.reuters.com/legal/pfizer-wins-1075-million-astrazeneca-us-cancer-drug-patent-trial-2024-05-17/
https://www.biopharmadive.com/news/astrazeneca-first-quarter-revenue-beat-cancer-drugs/714311/
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-beats-first-quarter-revenue-profit-estimates-2024-04-25/
https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer.html
https://www.globenewswire.com//news-release/2024/01/16/2810031/0/en/Kairos-Pharma-Doses-First-Patients-in-Phase-1-Trial-of-Lead-Drug-Candidate-ENV105-with-Osimertinib-to-Improve-Therapy-Sensitivity-for-EGFR-Driven-Lung-Cancer.html
https://www.fiercebiotech.com/biotech/astrazeneca-picks-friend-tagrisso-40m-upfront-deal
https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-granted-priority-review-us-patients-egfr-mutated-advanced-lung-cancer.html
https://www.fiercepharma.com/pharma/jjs-rybrevant-combo-beats-tagrisso-lung-cancer-progression-should-az-worry
https://endpts.com/jj-challenges-astrazeneca-in-lung-cancer-with-phiii-pfs-win/
https://www.prnewswire.com/news-releases/phase-3-mariposa-2-study-meets-dual-primary-endpoint-resulting-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-for-rybrevant-amivantamab-vmjw-plus-chemotherapy-with-and-without-la-301919084.html
https://www.globenewswire.com/news-release/2023/08/03/2718571/0/en/LianBio-Announces-First-Patient-Treated-in-Phase-1-Trial-of-SHP2-Inhibitor-BBP-398-in-Combination-with-Osimertinib-in-Patients-with-Non-Small-Cell-Lung-Cancer-with-EGFR-Mutations.html
https://www.globenewswire.com/news-release/2023/07/12/2703463/0/en/LianBio-Announces-Clinical-Supply-Agreement-with-AstraZeneca-in-China-to-Evaluate-BBP-398-in-Combination-with-Osimertinib-in-Patients-with-Non-Small-Cell-Lung-Cancer-with-EGFR-Muta.html
https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemo-improved-pfs-in-lung-cancer.html
https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial.html
https://www.prnewswire.com/news-releases/genprex-receives-safety-review-committee-approval-to-proceed-to-final-cohort-in-acclaim-1-phase-1-dose-escalation-trial-of-reqorsa-in-combination-with-tagrisso-in-advanced-non-small-cell-lung-cancer-301702436.html
https://www.prnewswire.com/news-releases/j-ints-bio-poster-presentation-of-further-preclinical-data-of-its-novel-oral-4th-generation-egfr-tki-jin-a02-at-the-2022-european-society-for-medical-oncology-congress-in-paris-france-esmo-2022-301625019.html
https://www.biospace.com/article/astrazeneca-makes-waves-in-japan-with-approvals-for-tagrisso-ultomiris-and-lynparza/
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/tagrisso-approved-in-japan-for-early-lung-cancer.html
https://www.clinicaltrialsarena.com/news/genprex-lung-cancer-therapy/
https://www.biopharmadive.com/news/eqrx-astrazeneca-lung-cancer-study-tagrisso-aumolertinib/629440/
https://www.globenewswire.com/news-release/2022/08/08/2493638/0/en/HUTCHMED-and-AstraZeneca-Announce-that-TAGRISSO-Plus-Savolitinib-Demonstrated-49-Objective-Response-Rate-in-Lung-Cancer-Patients-with-High-Levels-of-MET-Overexpression-and-or-Ampli.html
https://www.fiercepharma.com/pharma/astrazeneca-staves-last-tagrisso-generic-until-next-decade-now
https://www.prnewswire.com/news-releases/vivace-therapeutics-presents-new-preclinical-data-highlighting-strong-synergistic-activity-for-combination-of-vt3989-and-osimertinib-at-american-association-for-cancer-research-aacr-annual-meeting-2022-301520268.html
https://www.europeanpharmaceuticalreview.com/news/165991/nice-recommends-osimertinib-for-non-small-cell-lung-cancer-nsclc/
https://www.prnewswire.com/news-releases/new-data-on-rybrevant-amivantamab-vmjw-in-combination-with-lazertinib-show-early-activity-in-patients-with-non-small-cell-lung-cancer-whose-disease-has-progressed-after-both-osimertinib-and-platinum-based-chemotherapy-301380002.html
https://www.globenewswire.com/news-release/2021/09/08/2293176/0/en/HUTCHMED-and-AstraZeneca-Initiate-SANOVO-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-as-a-First-Line-Therapy-for-Certain-Lung-Cancer-Patients-in-China.html
https://www.prnewswire.com/news-releases/wclc-2021--mini-oral---ascentage-pharma-announces-latest-data-of-its-investigational-bcl-2bcl-xl-inhibitor-pelcitoclax-apg-1252-combined-with-osimertinib-in-patients-with-egfr-tki-resistant-non-small-cell-lung-cancer-301371959.html
https://www.business-standard.com/article/news-cm/zydus-cadila-receives-usfda-tentative-approval-for-osimertinib-tablets-121060300472_1.html
http://www.pmlive.com/pharma_news/azs_tagrisso_approved_for_egfr-positive_nsclc_in_the_eu_1370880#:~:text=AstraZeneca's%20(AZ)%20third%2Dgeneration,the%20ADAURA%20phase%203%20study
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214263
http://www.pharmatimes.com/news/eu_clears_tagrisso_for_early-stage_egfr-mutated_lung_cancer_1370872
http://www.pharmatimes.com/news/az_tagrisso_first_to_win_mhra_approval_under_project_orbis_1369493
https://www.fiercepharma.com/pharma/astrazeneca-s-tagrisso-imfinzi-may-be-slowed-by-covid-19-now-but-growth-coming-exec
http://www.pharmatimes.com/news/tagrisso_moves_closer_towards_eu_approval_for_early-stage_lung_cancer_1368442
https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-adjuvant-receives-positive-chmp-opinion.html
Market Place
Share 
